1 month retatrutide Retatrutide: The New Triple-Agonist Weight Loss Treatment VisualAbstract: Retatrutide reduces body weight

The aggressive titration tail in the 12 mg arm of the Phase 2 trial was strongly associated with higher rates of transient gastrointestinal adverse events, which is why researchers generally favor slower escalation when tolerability is prioritized

Preventive cardiology is not separate from brain health

Patients typically begin using GLP with a lower dose that is gradually increased over several weeks, which helps minimize the onset of any potential side effects and helps the body to adjust to the medication

VSMC prolif.: vascular smooth muscle cell proliferation

Psychopharmacology 240 , 13731386 (2023)

These advancements position microneedle technology as a transformative approach for delivering GLP-1 receptor agonists, offering the potential to improve therapeutic adherence, minimize systemic side effects, and support decentralized care models for diabetes management [43]